UK guideline for the use of HIV Post-Exposure Prophylaxis Following Sexual Exposure, 2015

International Journal of STD and AIDS

Volumn 27, Issue 9, 2016, Pages 713-738

  Cresswell, Fiona ^a   Waters, Laura ^b   Briggs, Eleanor ^c   Fox, Julie ^d   Harbottle, Justin ^e   Hawkins, David ^f   Murchie, Martin ^g   Radcliffe, Keith ^h   Rafferty, Paul ⁱ   Rodger, Alison ^j   Fisher, Martin ^a  

^a Worthing Hospital   (United Kingdom)

^b BASHH HIV Special Interest Group   (United Kingdom)

^c NAT (National AIDS Trust)   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e TERRENCE HIGGINS TRUST   (United Kingdom)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^g Society of Sexual Health Advisers   (United Kingdom)

^h Whittall Street Clinic ^*  (United Kingdom)

ⁱ HIV Pharmacy Association   (United Kingdom)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

AIDS; antiretroviral therapy; BASHH guidelines; HIV; HIV prevention; Post exposure prophylaxis (PEP); sexual exposure

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; BIBLIOGRAPHIC DATABASE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED PRACTICE; FLU LIKE SYNDROME; FOLLOW UP; HEALTH CARE POLICY; HETEROSEXUALITY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL HISTORY; MEN WHO HAVE SEX WITH MEN; NEEDLESTICK INJURY; NONHUMAN; OCCUPATIONAL EXPOSURE; PATIENT COUNSELING; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROSTITUTION; RASH; RISK REDUCTION; SAFE SEX; SEXUAL ASSAULT; SEXUAL HEALTH; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; UNITED KINGDOM; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; COITUS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HIV INFECTIONS; MALE; RISK ASSESSMENT; RISK FACTOR; SEXUAL BEHAVIOR;

ANTI-HIV AGENTS; COITUS; COST-BENEFIT ANALYSIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; POST-EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SEXUAL BEHAVIOR; UNITED KINGDOM;

EID: 84982873219     PISSN: 09564624     EISSN: 17581052     Source Type: Journal    
DOI: 10.1177/0956462416641813     Document Type: Article

References (136)

1. AIDS EAGo. Change to recommended regimen for post-exposure prophylaxis (PEP) 2015, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/351633/Change_to_recommended_regimen_for_PEP_starter_pack_final.pdf (2015, accessed 8 July 2015)
2. British Association for Sexual Health and HIV CEG. Framework for guideline development and assessment 2014, http://www.bashh.org/documents/GUIDELINESFRAMEWORKApril2015.pdf (2014, accessed 17 June 2015)
3. P.BennM.FisherR.Kulasegaram. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011). Int J STD AIDS2011; 22(12): 695–708.
4. Control CfD. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States Morbidity and Mortality Weekly Reports, 2005 / 54(RR02);1-202005, http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5402a1.htm (accessed 17 June 2015)
5. World Health Organisation. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children, http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement_dec2014/en/ (2014, accessed 19 March 2016)
6. Medicine ASfH. National guidelines for post-exposure prophylaxis after non-occupational and occupational exposure to HIV, http://www.ashm.org.au/pep-guidelines (2013, accessed 23 March 2016)
7. L.A.PintoA.L.LandayJ.A.Berzofsky. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Am J Med1997; 102(5B): 21–24.
8. A.I.SpiraP.A.MarxB.K.Patterson. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med1996; 183(1): 215–225.
9. O.BourryA.ManniouiP.Sellier. Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. Retrovirology2010; 7: 78–78.
10. R.M.GrantJ.A.WileyW.Winkelstein. Infectivity of the human immunodeficiency virus: estimates from a prospective study of homosexual men. J Infect Dis1987; 156(1): 189–193.
11. M.C.SamuelN.HessolS.Shiboski. Factors associated with human immunodeficiency virus seroconversion in homosexual men in three San Francisco cohort studies, 1984-1989. J Acquir Immune Defic Syndr1993; 6(3): 303–312.
12. E.VittinghoffJ.DouglasF.Judson. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol1999; 150(3): 306–311.
13. T.D.MastroD.Kitayaporn. HIV type 1 transmission probabilities: estimates from epidemiological studies. AIDS Res Hum Retroviruses1998; 14(Suppl 3): S223–S227.
14. R.A.RoyceA.SenaW.CatesJr. Sexual transmission of HIV. New Engl J Med1997; 336(15): 1072–1078.
15. R.F.BaggaleyR.G.WhiteM.C.Boily. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol2010; 39(4): 1048–1063.
16. V.DeGruttolaG.R.Seage3rdK.H.Mayer. Infectiousness of HIV between male homosexual partners. J Clin Epidemiol1989; 42(9): 849–856.
17. F.JinJ.JanssonM.Law. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS2010; 24(6): 907–913.
18. I.de Vincenzi. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. New Eng J Med1994; 331(6): 341–346.
19. R.H.GrayM.J.WawerR.Brookmeyer. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet2001; 357(9263): 1149–1153.
20. B.LeynaertA.M.DownsI.de Vincenzi. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol1998; 148(1): 88–96.
21. A.M.DownsI.De Vincenzi. Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. European Study Group in Heterosexual Transmission of HIV. J Acquir Immune Defic Syndr Human Retrovirol1996; 11(4): 388–395.
22. C.DonnellyW.LeisenringP.Kanki. Comparison of transmission rates of HIV-1 and HIV-2 in a cohort of prostitutes in Senegal. Bull Math Biol1993; 55(4): 731–43.
23. R.J.HayesK.F.SchulzF.A.Plummer. The cofactor effect of genital ulcers on the per-exposure risk of HIV transmission in sub-Saharan Africa. J Trop Med Hyg1995; 98(1): 1–8.
24. T.A.PetermanR.L.StoneburnerJ.R.Allen. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA1988; 259(1): 55–58.
25. J.del RomeroB.MarincovichJ.Castilla. Evaluating the risk of HIV transmission through unprotected orogenital sex. AIDS2002; 16(9): 1296–1297.
26. G.IppolitoV.PuroG.De Carli. The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection. Arch Int Med1993; 153(12): 1451–1458.
27. E.H.Kaplan. Modeling HIV infectivity: must sex acts be counted?J Acquir Immune Defic Syndr1990; 3(1): 55–61.
28. Control CfD. Case-control study of HIV seroconversion in healthcare workers after percutaneous exposure to HIV-infected blood France, United Kingdom and United States, January 1988–August 1994. Mor Mortal Wkly Rep1995; 44: 929–929.
29. D.M.CardoD.H.CulverC.A.Ciesielski. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. New Engl J Med1997; 337(21): 1485–1490.
30. D.M.Bell. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med1997; 102(5B): 9–15.
31. K.M.RichmanL.S.Rickman. The potential for transmission of human immunodeficiency virus through human bites. J Acquir Immune Defic Syndr1993; 6(4): 402–406.
32. V.WahnH.H.KramerT.Voit. Horizontal transmission of HIV infection between two siblings. Lancet1986; 2(8508): 694–694.
33. R.H.GrayM.J.Wawer. Probability of heterosexual HIV-1 transmission per coital act in sub-Saharan Africa. J Infect Dis2012; 205(3): 351–352.
34. R.B.RothenbergM.ScarlettC.del Rio. Oral transmission of HIV. AIDS1998; 12(16): 2095–2105.
35. J.A.RottingenD.W.CameronG.P.Garnett. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?Sex Transm Dis2001; 28(10): 579–597.
36. S.T.SadiqS.TaylorS.Kaye. The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS2002; 16(2): 219–225.
37. R.W.GitauS.M.GrahamL.N.Masese. Effect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy. AIDS2010; 24(17): 2733–2737.
38. A.WaldK.Link. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis2002; 185(1): 45–52.
39. D.J.Templeton. Male circumcision to reduce sexual transmission of HIV. Curr Opin HIV AIDS2010; 5(4): 344–349.
40. B.AuvertD.TaljaardE.Lagarde. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med2005; 2(11): e298–e298.
41. R.C.BaileyS.MosesC.B.Parker. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet2007; 369(9562): 643–656.
42. R.H.GrayG.KigoziD.Serwadda. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet2007; 369(9562): 657–666.
43. G.A.MillettS.A.FloresG.Marks. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. Jama2008; 300(14): 1674–1684.
44. P.L.VernazzaL.TroianiM.J.Flepp. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS2000; 14(2): 117–121.
45. S.Cu-UvinA.K.DeLongK.K.Venkatesh. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS2010; 24(16): 2489–2497.
46. C.C.TsaiP.EmauK.E.Follis. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol1998; 72(5): 4265–4273.
47. R.A.OttenD.K.SmithD.R.Adams. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol2000; 74(20): 9771–9775.
48. R.Le GrandB.VaslinJ.Larghero. Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. AIDS2000; 14(12): 1864–1866.
49. O.BourryP.BrochardS.Souquiere. Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. AIDS2009; 23(4): 447–454.
50. J.G.Garcia-LermaM.E.CongJ.Mitchell. Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci Transl Med2010; 2(14): 14ra4–14ra4.
51. S.TomkinsF.Ncube. Occupationally acquired HIV: international reports to December 2002. Euro surveillance: bulletin Europeen sur les maladies transmissibles. Eur Commun Dis Bull2005; 10(3): E050310 2–E050310 2.
52. R.S.SperlingD.E.ShapiroR.W.Coombs. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. New Engl J Med1996; 335(22): 1621–1629.
53. N.A.WadeG.S.BirkheadB.L.Warren. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. New Engl J Med1998; 339(20): 1409–1414.
54. M.SchechterR.F.do LagoA.B.Mendelsohn. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr: JAIDS2004; 35(5): 519–525.
55. A.W.E.TostevinS.CroxfordV.Delpech. Trends in transmitted drug resistance to HIV-1 in the UK since 2010. HIV Med2015; 16(Suppl. 2): 6–6.
56. M.E.RolandT.B.NeilandsM.R.Krone. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis2005; 41(10): 1507–1513.
57. G.F.S.HaidariJ.FoxJ.Fitzgerald. Acute HIV infection after initiation of post-exposure prophylaxis following sexual exposure: reasons, challenges and suggested management. HIV Med2015; 16(Suppl. 2)(P35): 23–23.
58. J.M.ParkinM.MurphyJ.Anderson. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet2000; 355(9205): 722–723.
59. B.EvansW.DugganJ.Baker. Exposure of healthcare workers in England, Wales, and Northern Ireland to bloodborne viruses between July 1997 and June 2000: analysis of surveillance data. BMJ2001; 322(7283): 397–398.
60. J.O.KahnJ.N.MartinM.E.Roland. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis2001; 183(5): 707–714.
61. A.BennettE.WainwrightE.Lord. The impact of the 2011 post-exposure HIV prophylaxis following sexual exposure (PEPSE) guidelines: a regional retrospective audit across three genitourinary centres. HIV Med2014; 15: 146–146.
62. B.SpiceS.BhaduriM.Sivaram. An audit of PEPSE in the West Midlands. HIV Med2014; 15: 131–131.
63. V.ParkashA.GarnerN.Gupta. Evaluation of PEPSE use in a district general hospital genitourinary medicine department. HIV Med2014; 15: 148–148.
64. F.AwosusiS.MashalR.O’Connell. A retrospective audit in a London HIV clinic, assessing the post-exposure prophylaxis for HIV following sexual exposure (PEPSE). HIV Med2014; 15: 39–40.
65. D.RowleyR.O’BaraM.Quinlan. Twenty-eight days later: audit of postexposure prophylaxis following sexual exposure (PEPSE) in a community sexual health clinic for men who have sex men. Int J STD AIDS2013; 24: 9–10.
66. K.JanmohamedL.BullD.Payne. Post exposure prophylaxis following possible exposure to HIV infection: an evaluation of 391 attendances at three central London sexual health clinics. Sex Transm Infect2012; 88.
67. S.DayA.MearsK.Bond. Post-exposure HIV prophylaxis following sexual exposure: a retrospective audit against recent draft BASHH guidance. Sex Transm Infect2006; 82(3): 236–237.
68. J.N.MartinM.E.RolandT.B.Neilands. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS2004; 18(5): 787–792.
69. A.van der StratenC.A.GomezJ.Saul. Sexual risk behaviors among heterosexual HIV serodiscordant couples in the era of post-exposure prevention and viral suppressive therapy. AIDS2000; 14(4): F47–F54.
70. C.R.F.K.WaldoB.Dillon“Close calls”: a teachable moment for long-term behaviour change. In: (ed). Innovative approaches to health psychology: prevention and treatment lessons from AIDS, Washington: APA, 2002.
71. Sheena McCormack SF and Martin Fisher. Updated BHIVA-BASHH position statement on PrEP in the UK 2015, http://www.bashh.org/documents/PreP_BHIVA_BASHH_Update_14June15_for%20consultation.pdf consultation.pdf (accessed 8 July 2015)
72. D.K.SmithJ.H.HerbstX.Zhang. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr2015; 68(3): 337–344.
73. G.GreubA.MazieroP.Burgisser. Spare post-exposure prophylaxis with round-the-clock HIV testing of the source patient. AIDS2001; 15(18): 2451–2452.
74. G.GreubS.GallantP.Zurn. Spare non-occupational HIV post-exposure prophylaxis by active contacting and testing of the source person. AIDS2002; 16(8): 1171–1176.
75. T.C.QuinnM.J.WawerN.Sewankambo. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. New Engl J Med2000; 342(13): 921–929.
76. D.DonnellJ.M.BaetenJ.Kiarie. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet2010; 375(9731): 2092–2098.
77. S.AttiaM.EggerM.Muller. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS2009; 23(11): 1397–1404.
78. M.S.CohenY.Q.ChenM.McCauley. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med2011; 365(6): 493–505.
79. A.B.T.RodgerV.CambianoP.Vernazza. HIV transmission risk through condomless sex If HIV+ partner on suppressive ART: PARTNER study, Boston: CROI, 2014.
80. N.AbdalaP.C.StephensB.P.Griffith. Survival of HIV-1 in syringes. J Acquir Immune Defic Syndr Hum Retrovirol1999; 20(1): 73–80.
81. J.C.KimL.J.MartinL.Denny. Rape and HIV post-exposure prophylaxis: addressing the dual epidemics in South Africa. Reprod Health Matters2003; 11(22): 101–112.
82. L.PlattE.JolleyT.Rhodes. Factors mediating HIV risk among female sex workers in Europe: a systematic review and ecological analysis. BMJ Open2013; 3(7): e002836–e002836.
83. UNAIDS. The GAP report 2014. http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport (accessed 19 March 2016)
84. B.Farrugia ParsonsK.FisherD.Cordery. Counselling improves follow-up HIV testing at Week 6 for HIV postexposure prophylaxis recipients. Sex Health2013; 10(3): 288–289.
85. L.BentzP.EnelB.Dunais. Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial. AIDS Care2010; 22(12): 1509–1516.
86. B.JamesA.I.H.WhitneyS.SanisettySrisowmyaP.Penaloza-MacMasterPablo. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature2014; 000: 1–4.
87. C.O’KeeffeN.NwokoloG.Whitlock. Does dropping day 5 PEP follow-up affect other outcomes?HIV Med2014; 15: 124–125.
88. Society EAC. EACS treatment guidelines V7.1 2014, http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html (accessed 22 June 2015)
89. Services DoHaH. Guidelines for the use of antitretroviral agents in HIV-1 infected adults and adolescents 2014, https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (accessed 11 March 2016)
90. S.TaylorS.Davies. Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. Curr Opin HIV AIDS2010; 5(4): 335–343.
91. J.M.BaetenD.DonnellP.Ndase. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New Engl J Med2012; 367(5): 399–410.
92. R.M.GrantJ.R.LamaP.L.Anderson. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med2010; 363(27): 2587–2599.
93. McCormack SDD (ed). Pragmatic Open-Label Randomised Trial of preexposure prophylaxis: The PROUD study. Conference of retroviruses and opportunistic infections, 23–26 February 2015. Seattle
94. Molina JMCC, Charreau I, Meyer L, et al. On-demand preexposure prophylaxis in man at high risk for HIV-1 infection. N Engl J Med 2015; 373(23): 2237–2246
95. S.A.RiddlerR.HaubrichA.G.DiRienzo. Class-sparing regimens for initial treatment of HIV-1 infection. New Engl J Med2008; 358(20): 2095–2106.
96. J.K.RockstrohJ.L.LennoxE.Dejesus. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis2011; 53(8): 807–816.
97. J.L.LennoxR.J.LandovitzH.J.Ribaudo. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med2014; 161(7): 461–471.
98. J.McAllisterP.ReadA.McNulty. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med2014; 15(1): 13–22.
99. D.AnnandaleC.RichardsonM.Fisher. Raltegravir-based post-exposure prophylaxis (PEP): a safe, well-tolerated alternative regimen. J Int AIDS Soc2012; 15: 132–132.
100. D.AnnandaleC.RichardsonM.Fisher. Raltegravir: alternative postexposure prophylaxis regimen?Int J STD AIDS2013; 24: 4–4.
101. Leal LLA, Torres B, Inciarte A, et al. (ed). Tenofovir/Emtricitabine Plus LPV/r vs MVC or Raltegravir for PEP: 2 randomized trials. Conference on retroviruses and opportunistic infections, 23–26th February 2015. Seattle.
102. S.M.PatelS.JohnsonS.M.Belknap. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr2004; 35(2): 120–125.
103. J.V.MadrugaP.CahnB.Grinsztejn. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet2007; 370(9581): 29–38.
104. A.LazzarinT.CampbellB.Clotet. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet2007; 370(9581): 39–48.
105. J.ScrivenerA.McOwanT.Griffiths. Recreational drug use among genitourinary medicine attendees: implications for service delivery. Int J STD AIDS2013; 24: 37–38.
106. Compendium EM. Summary of product characteristics for Kaletra, https://www.medicines.org.uk/emc/medicine/18442 (accessed 17 June 2015)
107. V.Diaz-BritoA.LeonH.Knobel. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther2012; 17(2): 337–346.
108. G.FatkenheuerN.JungH.Jessen. Darunavir(DRV)/r-based PEP versus standard of care (SOC) - the randomized PEPDar study. Top Antivir Med2014; 22(e–1): 497–497.
109. I.MassudW.AungA.Martin. Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. J Virol2013; 87(16): 8952–8961.
110. A.MilinkovicA.Arenas-PintoN.Brima. Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra® in combination with Truvada® for HIV post exposure prophylaxis (MiPEP Trial). Eur AIDS Clin Soc. 2015.
111. M.H.R.Authority. Domperidone: risks of cardiac side effects - indication restricted to nausea and vomiting, mew contraindications, and reduced dose and duration of use. Drug Saf Update2014; 7(10): A1–A1.
112. Characteristics RSoP. Electronic medicines compendium, http://www.medicines.org.uk/emc/medicine/20484/SPC/ (accessed 22 June 2015)
113. K.H.MayerM.J.MimiagaM.Gelman. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr2012; 59(4): 354–359.
114. E.VispoA.MenaI.Maida. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J antimicrob Chemother2010; 65(3): 543–547.
115. B.T.SchleenvoigtJ.P.FobiweP.M.Keller. HIV post exposure prophylaxis induced bicytopenia: a case report. AIDS Res Ther2014; 11(1): 11–11.
116. N.H.N.de VriezeM.S.van RooijenM.S.van de Loeff. Additional gonorrhea and Chlamydia Infections found with rapid follow-up screening in men who have sex with men with an indication for HIV postexposure prophylaxis. Sex Transm Dis2014; 41(8): 515–517.
117. Brook G, Bhagani S, Kulasegaram R, et al. United Kingdom national guideline on the management of the viral 1 hepatitides A, B & C 2015, http://www.bashh.org/BASHH/Guidelines/Guidelines/BASHH/Guidelines/Guidelines.aspx. (accessed 8 July 2015)
118. F.V.CresswellM.FisherD.J.Hughes. Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection. Clin Infect Dis2015; 60(2): 263–266.
119. Compendium EM. Truvada summary of product characteristics, https://www.medicines.org.uk/emc/medicine/15826 (accessed 1 June 2015)
120. A.JacksonG.MoyleV.Watson. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. J Acquir Immune Defic Syndr2013; 62(3): 275–281.
121. T.HawkinsW.VeikleyR.L.St Claire3rd. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr2005; 39(4): 406–411.
122. England N. Specialised services circular - pre-exposure prophylaxis (PrEP) to prevent HIV: clarification of commissioning position, www.bashh.org/documents/HIV%20PEPSE%202015%20Consultation%20Doc.pdf Position regarding PrEP April 2015.pdf (accessed 1 June 2015)
123. G.WritingI.WilliamsD.Churchill. British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). HIV Med2014; 15(Suppl 1): 1–85.
124. E.HamlynF.M.EwingsK.Porter. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PloS One2012; 7(8): e43754–e43754.
125. AIDS EAGo. HIV post-exposure prophylaxis: guidance from the UK Chief Medical Officers’ Expert Advisory Group on AIDS, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/203139/HIV_post-exposure_prophylaxis.pdf (accessed 12 July 2015)
126. S.de SilvaR.F.MillerJ.Walsh. Lack of awareness of HIV post-exposure prophylaxis among HIV-infected and uninfected men attending an inner London clinic. Int J STD AIDS2006; 17(9): 629–630.
127. M.JoshiA.BasraH.Webb. Awareness of post-exposure prophylaxis after sexual exposure (PEPSE) in patients attending an inner city HIV treatment centre. HIV Med2012; 13: 85–85.
128. E.PughM.PakianathanC.McCormick. The sexual health behaviour of HIV positive patients in an urban UK cohort. HIV Med2012; 13: 17–17.
129. S.RoedlingI.ReevesA.J.Copas. Changes in the provision of post-exposure prophylaxis for HIV after sexual exposure following introduction of guidelines and publicity campaigns. Int J STD AIDS2008; 19(4): 241–242.
130. M.JoshiA.BasraC.McCormick. Post-exposure prophylaxis after sexual exposure (PEPSE) awareness in an HIV-positive cohort. Int J STD AIDS2014; 25(1): 67–69.
131. S.D.PinkertonD.R.Holtgrave. How HIV treatment advances affect the cost-effectiveness of prevention. Med Decis Mak2000; 20(1): 89–94.
132. F.NakagawaA.MinersC.J.Smith. Projected lifetime healthcare costs associated with HIV infection. PloS One2015; 10(4): e0125018–e0125018.
133. S.D.PinkertonJ.N.MartinM.E.Roland. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Int Med2004; 164(1): 46–54.
134. S.D.PinkertonJ.N.MartinM.E.Roland. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS2004; 18(15): 2065–2073.
135. D.GuinotM.T.HoI.M.Poynten. Cost-effectiveness of HIV nonoccupational post-exposure prophylaxis in Australia. HIV Med2009; 10(4): 199–208.
136. J.BryantL.BaxterS.Hird. Non-occupational postexposure prophylaxis for HIV: a systematic review. Health Technol Assess2009; 13(14)::iii, ix–x, 1–60.